Effect of anti-obesity agent HSG4112 on overweight and obese patients following 12 weeks of oral treatment: a study protocol for a randomised, double-blind, placebo-controlled, parallel-group, phase 2a clinical trial

• Main Authors: Kyungha Min (Author), Bumjo Oh (Author), Hye Yeon Koo (Author), Yang-Hyun Kim (Author), Ji-Won Lee (Author), Sangsub Lee (Author), Youngah Kim (Author), Hyuktae Kwon (Author)
• פורמט: ספר
• יצא לאור: Frontiers Media S.A., 2023-08-01T00:00:00Z.
• נושאים: article
• גישה מקוונת: Connect to this object online.

Background: Glaceum Inc. has proposed HSG4112, a structural analogue of glabridin, as a novel anti-obesity compound. Animal studies and phase I human trials have shown that HSG4112 improves energy consumption, normalises weight, and is safe and drug-resistant. Based on these results, the company pla...